COMP <GO>
APVO vs HCWB // EV/EBITDA & P/E VALUATION
Aptevo Therapeutics Inc. (NASDAQ) VS. HCW Biologics Inc. (NASDAQ) • 15-METRIC TALLY: APVO 1
— HCWB 2
■ METRIC PARITY
LAST: $1.36 (+4.62%) • MKT CAP: $2.5M
valuation
—
LAST: $1.18 (-3.28%) • MKT CAP: $2.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APVO VS. HCWB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APVO | HCWB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 20.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | APVO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.9 | 31.3 | -4.42 | HCWB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.5M | $2.6M | -$188.2K | HCWB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APVO REV | HCWB REV | APVO GROSS % | HCWB GROSS % | APVO FCF | HCWB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $54.2K | — | 20.0% | -$25.6M | -$13.4M |
| FY 2024 | $0 | $2.6M | — | 37.4% | -$23.8M | -$14.5M |
| FY 2023 | $0 | $0 | — | — | -$11.7M | -$22.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APVO // BETA —
HCWB // BETA —